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INTRODUCTION 
Solid oral dosage forms has been one of the most 
suitable and widely accepted by the patient for the 
delivery of therapeutic active drug
1
. The conventional 
tablet dosage form provides minimal amount of drug in 
the colon with undesirable adverse effect due to 
variation in the transit time. Hence, to target the drug 
directly to the site of action in the colon , there is need 
to develop colon targeted drug delivery systems that 
will enhance the therapeutic drug level, increases the 
bioavailability of active medicament and reduce the 
dose of drug 
2
. 
Targeting of drugs to colon is effective and safe for the 
treatment of various colonic diseases like irritable 
bowel disease (IBD), intestinal amoebiasis, 
constipation, Crohn’s disease, ulcerative colitis, 
carcinomas and infections etc 
[5]
.  At present these 
disease are often poorly & inefficiently managed either 
by oral route, in which oral drugs are largely absorbed 
before they rich the colon or by rectal route of 
administration which is less acceptable. The colon 
specific drug delivery system (CDDS) should be 
capable of protecting the drug up to rich the colon i.e., 
drug release & absorption should not occur in the 
stomach as well as the small intestine & neither the 
bioactive agent should be degraded in either of 
dissolution site but only released & absorbed once the 
system reaches the colon
 2
. Absorption and degradation 
of the active ingredient in the upper part of GIT is the 
major problem with the delivery of drugs by the oral 
route and must be overcome for successful colonic drug 
delivery. 
Time dependent, pH dependent, microbiologically 
controlled, multiparticulate and luminal pressure 
controlled system are the latest approaches of drug 
delivery to the colon
3
. However, a disadvantage of pH 
dependent system is that a substantial amount of drug 
may be released in the small intestine before the 
delivery system arrives in the colon and limitation of 
time dependent release system is that they are not able 
to sense any variation in the upper GIT transit time.  
Hence, Microbial triggered delivery system is most 
convenient and highly site specific approach for 
targeting drug to colon than all targeting system. Drug 
releases when the polysaccharides are degraded by the 
bacteria of colonic microflora. Different 
polysaccharides have been reported for colon targeting 
as carriers. Most commonly used polysaccharides are 
guar gum, chitosan, pectin and xanthan gum etc
2,4,6,7
. In 
compression coated tablets drug present in inner core, 
surrounded by outer layer which contain polymer and 
other excipients. Outer coat degraded only in the 
colonic region by bacterial enzymes and subsequent 
drug releases in colon. 
Tenoxicam chemically 4 –hydroxy –2 – methyl – n-
(pyridinyl-2-yl) -2h-thieno [2, 3-e]-1,2–thiazine–3-
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carboxamide1, 1-dioxide, a Non steroidal anti-
inflammatory drug. It is used to relieve inflammation, 
swelling, stiffness
 8, 9, 10
 i.e. it is used to relieve pain and 
inflammation of inflammatory bowel disease, ulcerative 
colitis, chron’s disease and rheumatic arthritis. The dose 
of Tenoxicam is 10-20 mg daily by mouth. Tenoxicam 
is completely absorbed after oral administration
 12
. 
Tenoxicam has long elimination half life (60-75hr). For 
colon targeted drug delivery drug has good absorption 
and solubility profile in colon.   
Tenoxicam works by blocking the action of a substance 
in the body called cyclo-oxygenase (COX). COX is 
involved in the production of various chemicals in the 
body, some of which are known as prostaglandins. 
Prostaglandins are produced by the body in response to 
injury and certain diseases and conditions and cause 
pain, swelling and inflammation. Tenoxicam blocks the 
production of these prostaglandins and is therefore 
effective at reducing inflammation and pain
 11
.    
The aim of present investigation was to use the 
inexpensive, naturally and abundantly available 
polysaccharide such as guar gum for colon targeted 
drug delivery. Guar gum is natural non-ionic 
polysaccharides derived from seeds of Cyamopsis 
tetragonolobus (family: leguminaciae). It consists of 
linear chains of (1→4)-β-D-mannopyranosyl units with 
α-D-galactopyranosyl units attached by (1→6) linkage. 
Cross linked guar-gum has been used as a drug carrier 
in matrix tablets. It was concluded that guar-gum is 
suitable for preparation of colon specific formulations 
and is suitable as a carrier for drug that are not soluble 
in water
 4, 13, 14
. In this study, Hydroxyl Propyl Methyl 
Cellulose (HPMC) in combination with Guar gum was 
used to develop colonic delivery of Tenoxicam. HPMC 
was used to modify the drug release and improve the 
mechanical properties such as hardness of compression 
coated tablets. 
The present investigation deals with development of 
microbial triggered systems for delivering Tenoxicam 
into the colon and provided “proof of concept” data for 
natural polysaccharides preparations designed for 
colonic drug delivery. 
MATERIAL AND METHODS 
Tenoxicam was a gift sample from Ramdev Chemicals, 
Mumbai, India, Avicel pH101, HPMC K4M and Guar 
gum etc. procured from Loba Chemicals, Mumbai, 
India. All other ingredients were of analytical grade  
Infrared Spectroscopy of drug 
17
: 
The drug-excipient interaction study was carried out by 
using Infrared Spectroscopy. FTIR study was carried 
out to check compatibility of drugs with excipient. IR 
spectrum of drugs, physical mixture and optimized 
formulation were determined on Fourier Transform 
Infrared spectrophotometer (FTIR, Alpha-E, and 
Bruker). The base line correction was done then 
spectrum was run. 
DSC of Pure Drug 
18
: 
The drug-polymers compatibility was confirmed by 
differential scanning calorimetric (DSC), which was 
carried out by heating drug, and the formulated drug 
formulations separately from 0°C to 300°C at the 
heating rate of 10°C/min in a nitrogen environment of 
flow rate 20.0 ml/min. Aluminium pans and lids were 
used and temperature calibrations were performed 
periodically using melting transition of indium as 
standard. Sample size of 7.5mg used for analysis. The 
instrument used was SDT Q600 V20.9 Build 100 
differential scanning calorimeter with Universal V4.5 
software. 
Preparation of Tenoxicam core Tablets: 
The core tablets of Tenoxicam for compression coating 
were prepared by direct compression technique. Each 
core tablet (50 mg) consist of 10 mg tenoxicam, 39.50 
mg Avicel PH101, and 0.5 mg magnesium stearate. The 
powders were thoroughly mixed and passed through 
mesh (60μm). The uniformity of mixing was assessed 
by conducting content uniformity tests on the samples 
of powder mix. The mixture was compressed into 
tablets using KBr press with an applied force of 500 
kg/cm
-1
 using 4 mm round, Flat punch. The thickness 
and crushing strength of core tablets were measured. 
Compression coating of Tenoxicam core tablets: 
The coating materials of 150mg Guar Gum in 
combination with 10%, 20%, and 30% HPMC 
respectively were used to prepare coats respectively as 
shown in table 1. Half the amount of compression 
coating material was placed in the die cavity followed 
by carefully centering the core tablet and addition of the 
remaining coat weight. The coating material was then 
compressed around the core tablets using KBr press at 
an applied force of 1500 kg/cm-
1
 using 8 mm round, flat 
punch. The prepared tablets were tested for the 
uniformity of weight, drug content, mechanical 
properties (hardness and friability) and drug release 
characteristics. The strength of compression coat tablet 
was determined. 
 
Table 1: Composition of Guar Gum and HPMC used to cover Tenoxicam core tablets 
 
 
 
 
Formulation code Coat weight 
(mg) 
Content (mg) 
Guar Gum HPMC 
F1 150 135 15 
F2 150 120 30 
F3 150 105 45 
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Characterization of Tenoxicam compression coated 
tablets
 20, 21, 22
: 
The prepared tablets were evaluated for weight variation, 
hardness, friability and drug content  
Swelling study: 
Initial diameter, height and weight of individual matrices 
(S0) were measured and were placed in a dissolution 
medium (Phosphate buffer pH 6.8) at 37±0.5
o
C. Swollen 
tablets after specific time intervals (3, 6, 9, 12 and 24) 
were withdrawn from the medium, extra buffer present 
on the matrix surface was gently wiped with the soft 
tissue and individual diameter, height and weight (S1) 
were measured at predetermined time intervals. Percent 
of the radial (diameter) and axial (height) swelling of 
tablet and percent water uptake was calculated according 
to the following formula 
29
.    
Percent swelling (Sw) = [(S1-S0)/S0] × 100 
Where, S1 and S0 are the diameter or height of swollen 
tablets respectively. The percentage swelling of the 
original tablet was calculated and plotted vs. Time. 
Preparation of rat caecal content 
25
: 
Committee for the Purpose of Control and Supervision of 
Experiments of Animals (CPCSEA).The Institutional 
Animal Ethical Committee (IAEC) of Tatyasaheb 
College of Pharmacy, Warananagar, Maharashtra, India 
has approved the experimental protocols for this work 
(IAEC/TKCP/2014/14). 
The caecal contents were obtained from Wistar rats 
weighing 150-200 g, after pre-treatment with oral 
administration of 2mL of 1% w/v of polymer dispersion 
(i.e. Guar gum) in water for 3 days. Thirty minutes 
before starting drug release studies, each rat was killed 
by spinal traction, after which abdomens were opened, 
dissected, and immediately transferred to pH 6.8 
phosphate buffer previously bubbled with CO2. The 
caecal bags were then opened; their contents were 
individually weighed, homogenized, and then suspended 
in pH 6.8 phosphate buffer to give the desired 
concentration of 2% (w/v) of caecal content. As the 
caecum is naturally anaerobic, all these operations were 
carried out under CO2.  
In vitro drug release studies: 
The ability of the prepared tablets to retard drug release 
in the physiological environment of the stomach and 
small intestine was assessed by conducting drug release 
studies in stomach and small intestine pH, respectively. 
Dissolution test was conducted in USP I apparatus at 100 
rpm and a temperature of 37±0.5°C.The tablets were 
tested for drug release for 2 hours in acidic buffer of pH 
1.2 (900 ml), pH 7.4 phosphate buffer for 3 hours and 
phosphate buffer pH 6.8 for 19 hours with or without rat 
caecum content.  5ml of each sample was withdrawn at 
1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, and 24 hrs time and 
replaced with an equal volume of fresh media. The 
content of tenoxicam in the withdrawn samples was 
analyzed spectrophotometerically
 30
. 
Release kinetics: 
Data obtained from the in-vitro release studies of 
compression coated tablet of Tenoxicam formulations, 
were fitted to various kinetic equations such as zero 
order, first order, Higuchi model, Korsmeyer-Peppas 
model
 24
. 
Stability Studies: 
The optimized formulation was subjected for one month 
stability study at room temperature. The selected 
formulations were packed in aluminium foil in tightly 
closed Container. Formulations were stored at room 
temperature for one month. After one month interval, 
placed sample were analyzed for physical appearance, 
Drug content, in-vitro dissolution study, Hardness, 
thickness. 
RESULTS AND DISCUSSION 
Drug –excipients compatibility study: 
The overlay of IR spectrum of drug and physical mixture 
is shown in Figure 1 and table 2, which shows that 
peaks observed in spectrum of pure drug at wave number 
1144 cm 
-1
, 1199 cm 
-1
, 1388 cm 
-1
, 1420 cm 
-1
, 1493 cm 
-
1
 were also observed in spectrum of physical mixture. No 
significant changes in peak pattern in the IR spectra of 
pure Drug and physical mixture indicates that there is no 
interaction between pure drug and polymer. 
 
Table 2: Comparative FTIR Study of drug and polymer 
 
Name of 
Compound 
C-O stretching -O-H 
bending 
CH3 
deformation 
Heterocyclic 
ring 
-C-H deformation 
Tenoxicam 1144 cm 
-1
 1199 cm 
-1
 1388 cm 
-1
 1420 cm 
-1
  1493 cm 
-1
 
Tenoxicam and 
HPMC 
1142 cm 
-1
 1199 cm 
-1
 1385 cm 
-1
 1420 cm 
-1
  1492 cm
-1
 
Tenoxicam and 
Guar Gum 
1144 cm 
-1
 1199 cm 
-1
 1387 cm 
-1
 1420 cm 
-1
 1493 cm 
-1
 
Physical mixture of 
all ingredients 
1442 cm 
-1
 1190 cm 
-1
 1387 cm 
-1
 1418 cm 
-1
 1491 cm 
-1
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Figure 1: Overlay of FTIR spectrum of (A) Tenoxicam (B) Physical mixture of Tenoxicam and HPMC K4M (C) 
Physical mixture of Tenoxicam and Guar Gum (D) Physical mixture of all ingredients.  
 
 
Figure 2: Overlay of DSC Thermogram of (A) Tenoxicam (B) Optimized formulation F1  
 
Figure 2 shows the DSC thermographs of pure drug 
Tenoxicam and formulation F1. Thermographs obtained 
by DSC studies, revealed that the DSC thermogram of 
the drugs depicts a sharp exothermic peak at 212.5
o
C 
reflects the pure crystalline state of the drug and that of 
the drug in the formulation F1 depicts a exothermic peak 
at 216.34
o
C with marked decrease in sharpness. The 
sharpness of peak in formulation F1 decreased due to 
low concentration of Tenoxicam drug in formulation i.e. 
due to dilution of drug. As there is no much difference 
in the melting point of the drug in the thermograms of 
drug and that of in the formulation F1. It may be 
concluded that, the drug was in the same pure state even 
in the formulation without interacting with the polymers 
18
. 
Physical properties of tablets: 
The hardness of prepared tablets was found to be in the 
range of 5.30±0.11to 6.02±0.38kg/cm
2
, a value which 
indicates good strength. Thickness of all tablets was 
found to be in the range of 2.13 ± 0.05 to 2.23±0.5 mm. 
For weight variation test, the Pharmacopoeial limit for 
percent deviation for tablets weighing up to 250 mg is 
not more than 7.5%. The average percent deviation of 
all tablets was found to be within the limit; hence all 
formulation passes the weight variation test. The values 
of friability for all these formulations were less than the 
limit of 1% which is given in the IP. The friability was 
found in these formulations shows a good strength of 
tablets to withstand abrasion during transportation and 
general handling. Drug content of core tablet was found 
to be 101.17±0.20 %.  As per the IP specification drug 
content for tablets must be in the range of 85 to 115%. 
Thus, formulation passes the uniformity of drug content 
test as shown in table 3. 
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Table 3: Physical properties of compression coated tablets of Tenoxicam 
 
Batch code 
Parameter 
Diameter 
(mm ± SD) a 
Thickness 
(mm ± SD) b 
Hardness 
(kg/cm2± SD) c 
Friability 
(%±SD) d 
Weight variation 
(%) e 
F1 8.2±0.23 2.16±0.1 5.30±0.11 0.41±0.12 2 
F2 8.2±0.17 2.23±0.5 5.50±0.11 0.33±0.5 1 
F3 8.3±0.32 2.13±0.05 6.02±0.38 0.26±0.15 0.5 
a (n=3±SD), b (n=3±SD), c (n=3±SD), d (n=20±SD), e (n=20±SD) 
 
Swelling studies: 
 Measurement of swelling rates of different matrices 
were carried out to gain insight into the observed 
phenomena of drug release with the rates of polymer 
hydration and to evaluate the extent of water 
penetration into the tablets. The graphs of water uptake, 
axial and radial expansion for F1 are enumerated in 
Figure 3. It is evident that water uptake was 
continuously rising throughout the study. This supports 
the observation that the diffusion was predominant. 
Figure 3 shows the results of water uptake, axial and 
radial expansion for formulation F1. Though water 
uptake was continuously increasing with time, the radial 
and axial expansion was almost constant after 12 hr. 
This suggests the role of erosion to maintain constant 
diffusional path length because of proper 
synchronization between erosion and diffusion 
29
. 
 
 
Figure 3: Swelling study of formulation F1 including % water uptake, % axial swelling, % radial Swelling. 
 
In-vitro drug release studies: 
The mean drug release from the tablets F1, F2, F3 after 
the first 5 hr was 8.21±0.15%, 8.63±0.3% and 
8.07±0.3% respectively. At the end of 24 hr, the mean 
% drug release was 40.58±0.12%, 36.13±0.3% and 
27.72±0.15%.  As the concentration of HPMC 
increased, drug release was decreased. The increase in 
drug release could be explained due to HPMC creates a 
porous structure of the coat and consequently increases 
Guar Gum leaching and drug released. However further 
increase in HPMC % to 20% and 30% of the 
compression coat caused a reduction in gum leaching, 
with a consequent decrease in drug release as shown in 
Figure 4. Higher concentration of HPMC would reduce 
the free water volume and increase the viscosity of the 
coat causing a reduction in the polymer leaching and 
subsequent reduction in drug release 
[25]
.  Based on 
these results, F1 batch optimized for further in-vitro 
dissolution study using rat caecal content. Since, the % 
drug release at the end of 5hr which was expected time 
for the arrival of dosage form in the colon was found to 
be 8.21±0.15% and 40.58±0.12% drug release was 
achieved after 24 hr which is higher as compared to F2 
and F3 batch.   
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Figure 4: Release profile of Tenoxicam in formulation F1 to F3 without rat caecal content. 
 
As shown in Figure 5, the mean drug release from the 
tablet F1 after the first 5 hr was 7.54±0.5%. At the end 
of 24 hr, the mean % drug release was 94.54±0.4% in 
rat caecal medium. The maximum drug release after 
24hr in rat caecal medium was significantly higher in 
comparison with the drug release in control medium. 
This can be explained as the release of Tenoxicam in 
the physiological environment of colon is due to 
microbial degradation of Guar Gum. 
 
 
Figure 5: Release profile of Tenoxicam in formulation F1 using rat caecal content. 
 
Drug Release Kinetics
 23, 24
: 
Table 4 shows optimized batch F1 followed 
Koresmeyer-Peppas model indicate significant 
contribution of diffusion and also showed exponent n 
value between 0.5 and 1 which indicate non-fickian 
diffusion and furthermore together with the good fitting 
of Zero order model indicating erosion controlled 
release i.e. release was found to be both erosion and 
diffusion controlled 
    
 
 
Table 4: Release kinetics of optimized batches 
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1 Zero order 0.937 
2 Koresmeyer-
Peppas 
0.940 
(n=0.50) 
3 First order 0.915 
4 Higuchi 0.875 
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Stability Studies:  
Short-term stability studies were carried out on the 
optimized formulation F1.  The tablets of optimized 
batch were stable for 1 month at room temperature. 
There was no change in the physical appearance and 
drug content of the tablet during storage period. Mean 
(± S.D) drug content at the end of 1 month was found to 
be 99.21±0.5% indicating no significant change in the 
drug content. The % CDR during the drug release study 
conducted in the 0.1N HCL, PBS pH 7.4 and PBS pH 
6.8 after storage of 1 month was found to be 39.15± 
0.15% indicating no significant change in the in-vitro 
dissolution of tablet. The results indicated that, there 
were no any changes observed in tablet characteristics 
after stability study.
 
 
CONCLUSION 
Colon specific drug delivery system of Tenoxicam 
compression coated tablet was formulated successfully 
by using natural polymer such as Guar gum in 
combination with different concentration of HPMC. 
Based on in-vitro drug release study, it was concluded 
that compression coated tablets with combination of 
90% Guar gum and 10% HPMC could produce a 
successful drug targeting to the colon with minimal 
amount released in the stomach and small intestine. 
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